Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eptinezumab for PACAP-38 Induced Migraine
NCT05635604Completed
- Sponsor
- Dansk Hovedpinecenter
- Start
- Mar 2023
- Primary completion
- Aug 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Randomised trial of eptinezumab in migraine, sponsored by Dansk Hovedpinecenter. Primary endpoint: Subjective report of a migraine attack at 24 hours. Started Mar 2023; status: completed.
02
Drugs
eptinezumab
03
Conditions
migraine
Beyond the preview
Go deeper on NCT05635604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05635604.